Schering-Plough Relief on Partner Earnings
[?]
Submitted by BioHealth Investor, 24/7 Wall St.
Schering-Plough Corp. (SGP) is probably breathing a sigh of relief this morning after Merck’s earnings as it is partners with the drug giant on Vytorin and Zetia for cholesterol treatments.
The combined Vytorin & Zetia franchise was noted as having some $5.2 Billion in 2007 annual sales, with some $1.5 Billion being reported in the fourth quarter alone.
